Christine Rothe

Company: iOmx Therapeutics

Job title: Chief Development Officer

Seminars:

IOMX-0675, a Highly Differentiated Fully Human LILRB1 and LILRB2 Cross- Specific Antibody, Effectively Repolarizes the Tumor Microenvironment, Resulting in Potent Tumor Cell Killing in vitro and in vivo 4:00 pm

Describing the differentiated binding profile of IOMX-0675, antagonizing with high potency the two immuno-suppressive receptors LILRB1 and LILRB2 while sparing highly homologous immune-activating family members Translating into superiority in macrophage repolarization and immune cell activation, as compared to mono-specific or other dual-targeting antibodies Outlining the best-in-class therapeutic potential for IOMX-0675Read more

day: Conference Day One